Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of G-CSF (Neupogen/filgrastim) in Duchenne muscular dystrophy
MOH_2021-03-21_009857Phase 2Not yet recruiting
- Sponsor
- ד"ר מירה גינזברג
- Start
- Aug 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgrastim in Duchenne muscular dystrophy (DMD), sponsored by ד"ר מירה גינזברג. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
filgrastim
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2021-03-21_009857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-21_009857.